Targeting G(i/o) protein–coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy

GPCRs are highly desirable drug targets for human disease. Although GPCR dysfunction drives development and progression of many tumors, including breast cancer (BC), targeting individual GPCRs has limited efficacy as a cancer therapy because numerous GPCRs are activated. Here, we sought a new way of...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyu, Cancan, Ye, Yuanchao, Lensing, Maddison M., Wagner, Kay-Uwe, Weigel, Ronald J., Chen, Songhai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492335/
https://www.ncbi.nlm.nih.gov/pubmed/34343132
http://dx.doi.org/10.1172/jci.insight.150532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492335/
https://www.ncbi.nlm.nih.gov/pubmed/34343132
http://dx.doi.org/10.1172/jci.insight.150532

Ejemplares similares